Faculty Opinions recommendation of Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study.

Author(s):  
Heidi Klepin
2013 ◽  
Vol 24 (5) ◽  
pp. 1306-1312 ◽  
Author(s):  
C. Kenis ◽  
D. Bron ◽  
Y. Libert ◽  
L. Decoster ◽  
K. Van Puyvelde ◽  
...  

2014 ◽  
Vol 5 ◽  
pp. S16-S17
Author(s):  
J.W. Kim ◽  
S.-H. Kim ◽  
Y.J. Kim ◽  
K.-W. Lee ◽  
J.-O. Lee ◽  
...  

2021 ◽  
Vol 12 (8) ◽  
pp. S63-S64
Author(s):  
V. Depoorter ◽  
K. Vanschoenbeek ◽  
L. Decoster ◽  
H. De Schutter ◽  
P.R. Debruyne ◽  
...  

PLoS ONE ◽  
2015 ◽  
Vol 10 (9) ◽  
pp. e0138304 ◽  
Author(s):  
Jin Won Kim ◽  
Se-Hyun Kim ◽  
Yu Jung Kim ◽  
Keun-Wook Lee ◽  
Kwang-Il Kim ◽  
...  

2014 ◽  
Vol 32 (1) ◽  
pp. 19-26 ◽  
Author(s):  
Cindy Kenis ◽  
Lore Decoster ◽  
Katrien Van Puyvelde ◽  
Jacques De Grève ◽  
Godelieve Conings ◽  
...  

Purpose To compare the diagnostic characteristics of two geriatric screening tools (G8 and Flemish version of the Triage Risk Screening Tool [fTRST]) to identify patients with a geriatric risk profile and to evaluate their prognostic value for functional decline and overall survival (OS). Patients and Methods Patients ≥ 70 years old with a malignant tumor were included if a new cancer event occurred requiring treatment decision. Geriatric screening with G8 and fTRST (cutoff ≥ 1 [fTRST (1)] and ≥ 2 [fTRST (2)] evaluated) was performed in all patients, as well as a geriatric assessment (GA) evaluating social situation, functionality (activities of daily living [ADL] + instrumental activities of daily living [IADL]), cognition, depression, and nutrition. Functionality was re-evaluated 2 to 3 months after cancer treatment decision, and death rate was followed. Functional decline and OS were evaluated in relation to normal versus abnormal score on both screening tools. Results Nine hundred thirty-seven patients were included (October 2009 to July 2011). G8 and fTRST (1) showed high sensitivity (86.5% to 91.3%) and moderate negative predictive value (61.3% to 63.4%) to detect patients with a geriatric risk profile. G8 and fTRST (1) were strongly prognostic for functional decline on ADL and IADL, and G8, fTRST (1), and fTRST (2) were prognostic for OS (all P < .001). G8 had the strongest prognostic value for OS (hazard ratio for G8 normal v abnormal, 0.38; 95% CI, 0.27 to 0.52). Conclusion Both geriatric screening tools, G8 and fTRST, are simple and useful instruments in older patients with cancer for identifying patients with a geriatric risk profile and have a strong prognostic value for functional decline and OS.


2019 ◽  
Author(s):  
Guillaume Boudin ◽  
Heidi Solem Laviec ◽  
Lauriane Ghewy ◽  
Jean Luc Machavoine ◽  
Julie Denhaerynck ◽  
...  

Abstract Background: Early and systematic depression screening is recommended for older patients with cancer. The objective of this study is to evaluate the performance of three different mood disorder screening scales for detection of Major Depressive Disorder (MDD) in older patients with cancer. Methods: A prospective multicentric study was conducted in patients with cancer over 70 years of age, comparing three self-administered questionnaires: the 15-item Geriatric Depression Scale (GDS-15), the Hospital Anxiety and Depression Scale - Depression (HADS-D) and the Distress Thermometer (DT). Three weeks after initial assessment, in case of score above the standard cut-off, a reassessment of the patient’s mood was performed by the primary care physician, using the DSM-V MDD diagnostic criteria and the DT. Potential differences between an abnormal mood screening test and a confirmed MDD was assessed using variance analysis for each screening scale. Results: 93 patients with an average age of 81 years [70 - 95 years] were included. 66 patients had at least one abnormal score on one of the screening scales. A MDD was confirmed for 10 of the 36 reassessed patients (28%). Abnormal screening by the GDS-15 (p=0.021), the HADS-D (p=0.018) and the DT (p=0.045) was significantly associated with MDD diagnosis. Conclusions: The three screening scales enabled detection of MDD in older patients with cancer. Among the tested scales, the HADS-D could perform best in detecting MDD. However, these screening scales may not be sufficiently reliable for MDD screening in this population. Further studies are needed to confirm the results.


2005 ◽  
Vol 3 (4) ◽  
pp. 572 ◽  

By 2030, researchers estimate that 20% of the U.S. population will be 65 years or older. More than 50% of all new cancers in the United States occur in this patient population. In addition, the increased incidence and prevalence of cancer in older patients and the increased lifespan of older adults mean that cancer in older individuals is becoming an increasingly common problem. Specific issues include geriatric screening and assessment, preventing or decreasing complications from therapy, accounting for disease-specific issues, and managing patients who cannot tolerate standard treatment. The NCCN Senior Adult Oncology Panel has developed guidelines for addressing these issues and for assessing the risks and benefits of treatment in older patients with cancer. For the most recent version of the guidelines, please visit NCCN.org


Cancer ◽  
2018 ◽  
Vol 124 (18) ◽  
pp. 3753-3763 ◽  
Author(s):  
Cindy Kenis ◽  
Abdelbari Baitar ◽  
Lore Decoster ◽  
Jacques De Grève ◽  
Jean-Pierre Lobelle ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document